Business
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
CHICAGO, May 27, 2025--MAIA Biotechnology Announces Private Placement of Approximately $695,000
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/ea7a7210b2af98ce86edfb91bb07cbf3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o09uMbPX2s3P6p_KZsLpFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ea7a7210b2af98ce86edfb91bb07cbf3","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FWI2J0Hb696K1uz7rgMnzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ea7a7210b2af98ce86edfb91bb07cbf3","width":1000,"height":380}},"lazy":false},{"type":"text","content":"CHICAGO, May 27, 2025--(BUSINESS WIRE)--This is a correction of the announcement. The number of shares and expected proceeds from the private placement have been corrected to 463,332 shares and approximately $695,000. All other aspects of the announcement remain the same.","length":272,"tagName":"p"},{"type":"text","content":"The updated release reads:","length":26,"tagName":"p"},{"type":"text","content":"MAIA BIOTECHNOLOGY ANNOUNCES PRIVATE PLACEMENT OF APPROXIMATELY $695,000","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 463,332 shares of common stock at a purchase price of $1.50 per share, in a private placement to accredited investors and a Company director. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.71 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants). The warrants are exercisable commencing six-months following issuance and have a term of five years from the initial issuance date. The securities being sold to the Company director participating in the offering are being issued pursuant to the Company’s 2021 Equity Incentive Plan. The private placemen...